Nuvalent (NASDAQ:NUVL) Reaches New 52-Week High – Time to Buy?

Nuvalent, Inc. (NASDAQ:NUVL) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $123.70 and last traded at $123.72, with a volume of 671584 shares. The stock had previously closed at $123.60.

Analyst Ratings Changes

NUVL has been the subject of several recent analyst reports. Leerink Partners set a $165.00 target price on Nuvalent in a research note on Wednesday, June 3rd. Guggenheim cut shares of Nuvalent from a “buy” rating to a “neutral” rating and lowered their target price for the company from $151.00 to $124.00 in a report on Wednesday, June 10th. Lifesci Capital cut shares of Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price target for the company. in a research report on Tuesday, June 9th. Sanford C. Bernstein lowered Nuvalent from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $172.00 to $124.00 in a report on Wednesday, June 24th. Finally, TD Cowen downgraded Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 price target on the stock. in a research note on Tuesday, June 9th. Four equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $127.73.

Nuvalent Stock Performance

The stock has a market cap of $9.77 billion, a price-to-earnings ratio of -20.42 and a beta of 1.14. The stock’s 50 day moving average is $109.70 and its two-hundred day moving average is $105.13.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the prior year, the business posted ($1.18) EPS. On average, sell-side analysts predict that Nuvalent, Inc. will post -5.74 EPS for the current year.

Insider Buying and Selling

In related news, insider Deborah Ann Miller sold 5,500 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total transaction of $593,120.00. Following the completion of the sale, the insider directly owned 59,634 shares of the company’s stock, valued at $6,430,930.56. This trade represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO James Richard Porter sold 30,000 shares of Nuvalent stock in a transaction on Monday, June 8th. The shares were sold at an average price of $88.53, for a total transaction of $2,655,900.00. Following the completion of the transaction, the chief executive officer owned 324,879 shares in the company, valued at approximately $28,761,537.87. This trade represents a 8.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 115,523 shares of company stock valued at $11,409,713 over the last 90 days. Insiders own 5.02% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. HighVista Strategies LLC boosted its position in Nuvalent by 84.9% during the third quarter. HighVista Strategies LLC now owns 93,294 shares of the company’s stock worth $8,068,000 after purchasing an additional 42,834 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in shares of Nuvalent in the third quarter valued at about $1,297,000. Aberdeen Group plc increased its stake in shares of Nuvalent by 115.4% during the 4th quarter. Aberdeen Group plc now owns 165,177 shares of the company’s stock worth $16,615,000 after purchasing an additional 88,489 shares in the last quarter. Nicholas Investment Partners LP lifted its stake in Nuvalent by 29.2% in the 4th quarter. Nicholas Investment Partners LP now owns 160,483 shares of the company’s stock valued at $16,143,000 after buying an additional 36,305 shares in the last quarter. Finally, Cantor Fitzgerald L. P. purchased a new position in Nuvalent during the third quarter worth $1,946,000. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.